Genelux (GNLX) EBITDA (2022 - 2026)

Genelux's EBITDA history runs 5 years deep, the most recent figure standing at -$8.9 million for Q1 2026.

• In Q1 2026, EBITDA fell 18.8% year-over-year to -$8.9 million; the TTM figure through Mar 2026 stood at -$33.6 million (down 14.04% YoY), while the FY2025 annual figure was -$32.2 million, down 7.98% from the prior year.
• EBITDA was -$8.9 million for Q1 2026 at Genelux, up from -$9.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $6.3 million in Q3 2022 to a low of -$9.2 million in Q4 2025.
• Historically, EBITDA has averaged -$6.1 million across 5 years, with a median of -$7.0 million in 2023.
• The sharpest annual moves came in 2023 and 2025: EBITDA slumped 183.65% in 2023, then gained 4.35% in 2025.
• A 5-year view of EBITDA shows it stood at -$3.1 million in 2022, then plunged by 126.28% to -$7.0 million in 2023, then slipped by 29.07% to -$9.0 million in 2024, then dropped by 2.32% to -$9.2 million in 2025, then rose by 3.29% to -$8.9 million in 2026.
• The last three EBITDA figures came in at -$8.9 million (Q1 2026), -$9.2 million (Q4 2025), and -$7.9 million (Q3 2025), per Business Quant data.